SCHEMBL40675

SCHEMBL40675

CN(CCC(=O)O)Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 2/20 0.66
KDM4C Q9H3R0 2/20 0.66
CARM1 Q86X55 1/20 0.58
PRMT6 Q96LA8 1/20 0.58
PRMT8 Q9NR22 1/20 0.58
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
SIGMAR1 Q99720 3/20 0.55
TMEM97 Q5BJF2 3/20 0.55
LTA4H P09960 2/20 0.54
BCHE P06276 1/20 0.53
ACHE P22303 1/20 0.53
HTR7 P34969 1/20 0.52
APP P05067 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676817 0.89 KDM4A (0.67) KDM4AKDM4CCARM1PRMT6PRMT8
Hydrochloric Acid SCHEMBL8891865 0.87 KDM4A (0.68) KDM4AKDM4CCARM1PRMT6PRMT8
SCHEMBL7398852 0.87 KDM4A (0.74) KDM4AKDM4CSIGMAR1TMEM97HTR7
SCHEMBL5479984 0.87 CARM1 (0.56) KDM4AKDM4CCARM1PRMT6PRMT8
SCHEMBL7205122 0.86 KDM4A (0.76) KDM4AKDM4CSIGMAR1ACHEHTR7
SCHEMBL5522971 0.86 MEN1 (0.56) KDM4AKDM4CCARM1PRMT6PRMT8
SCHEMBL18117060 0.85 KDM4A (0.51) KDM4AKDM4CLTA4HACHEKMT2A
SCHEMBL7379295 0.85 CARM1 (0.55) KDM4AKDM4CCARM1PRMT6PRMT8
SCHEMBL13359820 0.85 CARM1 (0.59) KDM4AKDM4CCARM1PRMT6PRMT8
SCHEMBL5476106 0.84 CARM1 (0.53) KDM4AKDM4CCARM1PRMT6PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208955-A1 SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM RESEARCH TRIANGLE INSTITUTE 2024-06-27 US disclosed
EP-4304630-A1 SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM Research Triangle Institute (US) 2024-01-17 EP disclosed
WO-2022192126-A1 SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM RESEARCH TRIANGLE INSTITUTE (US) 2022-09-15 WO disclosed
EP-2591354-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2013-05-15 EP disclosed
EP-2590656-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2013-05-15 EP disclosed
WO-2012054110-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-04-26 WO disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 WO disclosed
WO-2010116132-A2 BISPHOSPHONATE COMPOUNDS FOR CHELATING RADIONUCLIDES KING'S COLLEGE LONDON (GB) 2010-10-14 WO disclosed
US-7291642-B2 Bradykinin-B1 antagonists, process for their preparation and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-06 US disclosed
EP-1812405-A1 NOVEL BRADYKININ B1 ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-01 EP disclosed
US-20060100219-A1 Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-05-11 US disclosed
WO-2006048209-A1 NOVEL BRADYKININ B1 ANTAGONISTS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS DRUGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-05-11 WO disclosed
EP-0528172-A1 (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists J. URIACH & CIA. S.A. (ES) 1993-02-24 EP disclosed
EP-0252504-B1 DIPHOSPHONIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 1990-06-20 EP disclosed
US-4927814-A Diphosphonate derivatives, pharmaceutical compositions and methods of use BOEHRINGER MANNHEIM GMBH (DE) 1990-05-22 US disclosed
US-4145432-A 6-ACYLORYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND A METHOD OF EFFECTING VASODILATION THEREWITH FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208955-A1 SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM RXFP3, RXFP1, RXFP4 KDM4A 1952/4885KDM4C 2402/4885CARM1 1081/4885
US-20060100219-A1 Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments BDKRB1, BDKRB2, MRGPRX1 KDM4A 2790/4885KDM4C 3585/4885CARM1 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.